Galectin-3 in chronic kidney disease.
Clin Chim Acta
; 559: 119727, 2024 Jun 01.
Article
en En
| MEDLINE
| ID: mdl-38750780
ABSTRACT
BACKGROUND AND AIMS:
High serum galectin-3 has been associated with adverse outcomes among dialysis patients, although its prognostic role remains unclear among individuals with earlier-stage chronic kidney disease. The present systematic review aims to evaluate the association of serum galectin-3 with survival, cardiovascular disease and kidney disease progression among non-dialysis chronic kidney disease patients.METHODS:
PubMed, Scopus, Web of Science, CENTRAL and Google Scholar were systematically searched till November 10, 2023. All observational studies assessing the prognostic role of serum galectin-3 in patients with non-dialysis chronic kidney disease were included.RESULTS:
Overall, 12 studies (10 cohort, 2 cross-sectional) were included, comprising 9,349 patients. The endpoint of survival was assessed in 5 studies, indicating a significant association between increasing serum galectin-3 levels and higher all-cause mortality risk (Hazard ratio per unit 1.22, 95 % confidence intervals-CI 1.05-1.41, ≥6 ng/mL 2.66, 95 % CI 1.68-4.23). Current evidence coming from 4 studies was inconclusive regarding the potential link of galectin-3 and kidney function decline, yielding conflicting results. No significant associations between serum galectin-3 and heart failure, cardiovascular events or death were consistently reported.CONCLUSIONS:
This systematic review supports the prognostic role of galectin-3 in chronic kidney disease, as its increased serum values may be associated with higher all-cause mortality risk. No clear role could be supported for serum galectin-3 regarding the prediction of cardiovascular disease or kidney disease progression.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Galectina 3
/
Insuficiencia Renal Crónica
Límite:
Humans
Idioma:
En
Revista:
Clin Chim Acta
Año:
2024
Tipo del documento:
Article